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n this issue of Diabetes, Miyashita et al. (1) provide
compelling new evidence that natriuretic peptides
(NPs) play a key role in the regulation of body
weight and energy metabolism. In a series of com-
plementary experiments, the investigators show that the
NP–cyclic guanosine monophosphate (cGMP) signaling
system increases the capacity for fat oxidation, activates
mitochondrial biogenesis, and prevents the deleterious
effects of a high-fat diet (HFD).
NPs are not new players in metabolic regulation. Since
the discovery of atrial natriuretic peptide (ANP) in 1980
(2), a large body of work has highlighted the multifaceted
roles of NPs in the regulation of blood volume and arterial
pressure. NPs are members of a family of structurally
similar but genetically distinct endogenous peptide hor-
mones. The NP family consists of at least three mamma-
lian peptides: atrial-, brain-, and C-type (ANP, BNP, and
CNP, respectively) (3). ANP and BNP preferentially bind
to a particulate guanylyl cyclase (GC) receptor called
GC-A, whereas CNP is the physiological ligand for GC-B
(4). Through their diuretic, vasodilatory, and antimito-
genic properties, the NPs play an important role in the
regulation of cardiovascular, renal, and endocrine ho-
meostasis (3–5).
New ﬁndings by Miyashita et al. convincingly demon-
strate that the NP-cGMP system also plays a role in the
regulation of fatty acid metabolism and body weight
regulation (Fig. 1). The researchers generated a series of
mouse models to investigate. BNP transgenic mice, which
overexpress BNP in the liver at supraphysiological levels
(100-fold compared with resting level), tended to be
leaner than wild-type mice. When challenged with HFD,
these mice resisted diet-induced obesity and insulin
resistance. They had lower total body fat, increased
whole-body oxygen consumption and fat oxidation, and
increased mitochondrial biogenesis in skeletal muscle.
The effect on fat metabolism was especially prominent
during the daytime when lipolysis in mice is maximally
activated. The reduced total fat mass in BNP transgenic
mice could explain their lower tissue lipid deposition in
the liver and skeletal muscle because body fat is a major
determinant of ectopic fat (6). Importantly, these effects
appear to be due to upregulation of mitochondrial biogen-
esis in muscle as the researchers nicely showed that
NP-cGMP turns on mitochondrial biogenesis in vitro in
C2C12 myotubes, a conﬁrmation of earlier ﬁndings (7).
That the second messenger, cGMP, regulates mitochon-
drial biogenesis is consistent with previous studies show-
ing that nitric oxide—through activation of the soluble GC
and cGMP signaling—promotes mitochondrial biogenesis
in skeletal muscle in response to calorie restriction in
rodents (8) and potentially in humans (9).
In parallel, the researchers found that mice with ubiq-
uitous overexpression of the downstream cGMP-
dependent protein kinase type I (cGK-I) were signiﬁcantly
leaner than their wild-type littermates and resisted HFD-
induced obesity. This was associated with increased fat
oxidation and energy expenditure in skeletal muscle and
brown fat through increased mitochondrial content and
increased expression of peroxisome proliferator–activated
receptor  coactivator (PGC)-1 and peroxisome prolif-
erator–activated receptor (PPAR)- genes, the two main
master regulators of mitochondrial biogenesis. Interest-
ingly, the researchers noticed giant intermyoﬁbrillar mito-
chondria in the skeletal muscle of cGK transgenic mice.
An intriguing aspect of the study was the ﬁnding that
HFD decreased the expression of the dominant NP recep-
tor, suggesting that HFDs might dampen the response to
NP stimulation and reduce mitochondrial biogenesis and
fat oxidation (Fig. 1, right panel). The downregulation of
GC-A and GC-B in skeletal muscle, white and brown fat
during HFD in parallel with the increased expression of
the NP clearance receptor (NPR-C) could be detrimental
in terms of energy balance. A low ratio of GC-A to NPR-C
expression in target tissues could reduce NP-cGMP signal-
ing and/or NP concentrations within the tissue (10). Fu-
ture experiments in both mice and humans should
carefully explore the possibility that attenuation of NP
signaling might dampen the effects of NP to activate
mitochondrial biogenesis and fat oxidation. This could be
critically important if the NP system is to be developed for
therapeutic purposes—a very attractive possibility given
the overall results of Miyashita et al.
A growing body of evidence suggests that NPs play a
role in the regulation of lipid metabolism through the
control of adipose tissue lipolysis (11). The GC-A receptor
and NPR-C were identiﬁed in rat and human white adipose
tissue (12,13). ANP and BNP both stimulate lipolysis in
isolated human fat cells through the activation of the GC-A
receptor and increased cGMP. CNP displays weak lipolytic
activity because of a low level of expression of GC-B in
human adipocytes (14,15). The downstream molecular
signaling pathway involves the activation of the cGK-I
isoform, which targets perilipin-A and one of the rate-
limiting enzymes of the lipolytic cascade hormone-
sensitive lipase (16). Phosphorylation of perilipin-A allows
active hormone-sensitive lipase to reach lipid droplets and
to hydrolyze triglycerides into free fatty acids and glycerol.
ANP could be particularly relevant during endurance
exercise where it contributes to lipolysis and lipid mobi-
lization (14). Consistent with a role for NP in the provision
of fatty acids to fuel exercise, infusion of low pharmaco-
From the
1Institute of Molecular Medicine, INSERM U858, Department of
Metabolism and Obesity, Toulouse, France; and the
2Clinical Research
Institute, Florida Hospital and the Burnham Institute for Medical Research,
Orlando, Florida.
Corresponding author: Steven R. Smith, steven.r.smith.md@ﬂhosp.org.
DOI: 10.2337/db09-1335
© 2009 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
See accompanying original article, p. 2880.
COMMENTARY
2726 DIABETES, VOL. 58, DECEMBER 2009 diabetes.diabetesjournals.orglogical doses of human ANPs in healthy volunteers in-
creases both plasma free fatty acid and whole-body lipid
oxidation (17). Lipid mobilization is independent of the
sympathetic nervous system (18). The work of Miyashita
et al. adds to this knowledge base by suggesting that
NPs and the cGMP system might be responsible for the
exercise-induced increases observed in skeletal muscle
mitochondria, which represents a major structural adap-
tation to exercise training. These new data also suggest
that the increased NP plasma levels observed in patients
with heart failure and other pathophysiological conditions
could lead to the same changes described by the research-
ers, such as increased fat oxidation and decreased body
weight. This possibility should be explored further.
The study by Miyashita et al. highlights the pivotal role
of NPs in the regulation of skeletal muscle mitochondrial
biogenesis and an increased capacity for fat oxidation in
vivo. The relevance of this system to the human condition
has been partly demonstrated during intravenous infusion
of ANP, head-down bed rest, and in the postprandial state
(19,20). Given that lipid availability upregulates lipid oxi-
dation pathways in muscle, the stimulation of lipolysis
probably adds to the direct effects of NP on skeletal
muscle mitochondrial biogenesis.
As is often the case, these new ﬁndings spur new
questions: How does the mitochondrial phenotype lead to
increased energy expenditure? Does NP-cGMP increase
energy expenditure through mitochondrial uncoupling? Is
increased spontaneous activity a factor? Oxygen consump-
tion was remarkably increased in transgenic mice in the
nighttime when mice become active looking for food,
suggesting this might be the case. Is skeletal muscle the
primary site for these effects, as suggested by the struc-
tural changes in muscle mitochondria? Future studies
should include transgene expression targeted to speciﬁc
tissues to determine the contribution of muscle and other
tissues in the observed resistance to HFD.
The compelling new data by Miyashita et al. together
with a growing body of literature suggest that NPs and the
cGMP signaling system should be a focus of new investi-
gation in the ﬁeld of energy metabolism. If the beneﬁcial
effects of the NP-cGMP system could be harnessed to
upregulate energy and fat metabolism without impacting
the “classic” role of NPs in renal and cardiovascular
functions, then we may just have a new weapon in the ﬁght
against obesity and diabetes.
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